Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/26412
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorZuluaga Salazar, Andrés Felipe-
dc.contributor.authorAgudelo Pérez, María-
dc.contributor.authorSalazar Giraldo, Beatriz-
dc.contributor.authorRodríguez Jaramillo, Carlos Andrés-
dc.contributor.authorVesga Meneses, Omar-
dc.date.accessioned2022-03-04T23:05:19Z-
dc.date.available2022-03-04T23:05:19Z-
dc.date.issued2004-
dc.identifier.issn0733-6373-
dc.identifier.urihttp://hdl.handle.net/10495/26412-
dc.description.abstractABSTRACT: Background: Legal use of GP in human and veterinary medicine has great impact in price regulation worldwide, but numbers of GP makers are increasing overwhelmingly. Beyond quality problems, concern is growing about the scientific basis of using bioequivalence (BE) as surrogate proof of TE, the accepted dogma. To test it, bactericidal efficacy of GP of PEN made in Colombia was compared in vitro and in vivo against the original compound (OC) in simultaneous experiments, employing the same methods required for new antimicrobials. Methods: Microbiologic assays with S. aureus ATCC 6538p and broth microdilution minimal inhibitory and bactericidal concentrations (MIC/MBC) were used to determine BE by comparison of standard curves (SC) and in vitro activity. The NMTIM used 6 week-old specific pathogen free ICR:CD-1 female mice weighting 25±2 g infected with S. aureus GRP-0057, a PEN-susceptible clinical isolante. The sigmoid dose-response model was applied to calculate by least squares nonlinear regression (NLR) pharmacodynamic parameters (PDP) like Emax and bacteriostatic dose (BD). SC were compared by linear curve fitting analysis (CFA), whole NLR by nonlinear CFA, individual PDP by nonlinear CFA and Wilcoxon-Mann-Whitney test (WMW), MIC/MBC by WMW. Results: All 5 GP were made in Colombia; 1 had greater amounts of PEN (intercept = 0.0052 vs 0.0041 mg/l, P<0.0001), but did not differ in MIC/MBC from the OC. Only 1 of the other 4 GP had lower MIC/MBC, 0.01/0.02 vs 0.07/0.10 mg/l for the OC (P = 0.013). Mice had 104.49-4.74 CFU/thigh (CFU/g) when treated with PEN 0.094-24 mg/kg for 24 hours (24h) divided q1h. At the end of therapy, untreated controls had 107.65-7.83 CFU/g (24h growth = 2.92-3.33 log10 CFU/g). All 5 GP failed TE: Emax = 2.01-3.26 vs 4.87 log10 CFU/g, and BD = 6.94-120.1 vs 1.65 mg/kg/24h for GP and OC respectively (P<0.0005). Conclusions: GP of PEN do not exhibit TE with the OC. Current criteria for BE and TE deserve review.spa
dc.format.extent1spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherAmerican Society for Microbiologyspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.titleDetermination of Therapeutic Equivalence (TE) of 5 Generic Products (GP) of Penicillin G (PEN) Using the Neutropenic Murine Thigh Infection Model (NMTIM)spa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGRIPE: Grupo Investigador de Problemas en Enfermedades Infecciosasspa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.citationtitleAbstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapyspa
oaire.citationstartpage40spa
oaire.citationendpage40spa
dc.rights.creativecommonsDerechos reservados - Está prohibida la reproducción parcial o total de esta publicaciónspa
dc.publisher.placeWashington, Estados Unidosspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsPenicilina G-
dc.subject.decsPenicillin G-
dc.subject.decsMedicamentos Genéricos-
dc.subject.decsDrugs, Generic-
dc.subject.decsEquivalencia Terapéutica-
dc.subject.decsTherapeutic Equivalency-
dc.description.researchgroupidCOL0005744spa
Aparece en las colecciones: Artículos de Revista en Ciencias Médicas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
AndresZuluaga_2004_DeterminationPenicillinNneutropenic.pdfArtículo de investigación7.26 MBAdobe PDFVisualizar/Abrir


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.